02 Pages : 9-17
http://dx.doi.org/10.31703/gpsr.2024(IX-II).02 10.31703/gpsr.2024(IX-II).02 Published : Jun 2024Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approaches, Challenges, and Future Prospects
Immunotherapy is a medical intervention in which certain immune system components are used to combat disease. Usually, immunotherapy works by helping the body fight off the offending substance by modifying it as well as boosting the immune system. Biologic therapy or biotherapy are additional terms for certain forms of immunotherapy. Different advances and novel approaches have been studied such as cancer vaccines, immune checkpoint inhibitors, monoclonal antibodies, etc. Oral immunotherapeutics are used in a variety of solid tumors and hematological malignancies but still, these immunotherapeutics have their own limitations and adverse effects. Management of these side effects and optimization of therapeutic benefits remains a challenge. Moreover, challenges such as patient selection, dose optimization, and medication resistance are major issues that hinder the widespread use of oral immunotherapeutics. However, the future of oral immunotherapy in oncology seems to be promising due to the new advancements and research done. New advancements hold the potential to revolutionize cancer therapy.
-
Cancer, ADCs, Immunotherapeutic, Oral Immunotherapeutic, Combination Therapies, Targeted Therapies, Adverse Effects, Challenges, Advancement in Immunotherapy
-
(1) Kalya Ahmad Sandhu
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
(2) Asawar Yameen
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
(3) Naima Zafar
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
(4) Hira Ali
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
(5) Usama Abid
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
(6) Mishkaat Raza
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
Cite this article
-
APA : Sandhu, K. A., Yameen, A., & Zafar, N. (2024). Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approaches, Challenges, and Future Prospects. Global Pharmaceutical Sciences Review, IX(II), 9-17. https://doi.org/10.31703/gpsr.2024(IX-II).02
-
CHICAGO : Sandhu, Kalya Ahmad, Asawar Yameen, and Naima Zafar. 2024. "Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approaches, Challenges, and Future Prospects." Global Pharmaceutical Sciences Review, IX (II): 9-17 doi: 10.31703/gpsr.2024(IX-II).02
-
HARVARD : SANDHU, K. A., YAMEEN, A. & ZAFAR, N. 2024. Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approaches, Challenges, and Future Prospects. Global Pharmaceutical Sciences Review, IX, 9-17.
-
MHRA : Sandhu, Kalya Ahmad, Asawar Yameen, and Naima Zafar. 2024. "Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approaches, Challenges, and Future Prospects." Global Pharmaceutical Sciences Review, IX: 9-17
-
MLA : Sandhu, Kalya Ahmad, Asawar Yameen, and Naima Zafar. "Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approaches, Challenges, and Future Prospects." Global Pharmaceutical Sciences Review, IX.II (2024): 9-17 Print.
-
OXFORD : Sandhu, Kalya Ahmad, Yameen, Asawar, and Zafar, Naima (2024), "Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approaches, Challenges, and Future Prospects", Global Pharmaceutical Sciences Review, IX (II), 9-17
-
TURABIAN : Sandhu, Kalya Ahmad, Asawar Yameen, and Naima Zafar. "Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approaches, Challenges, and Future Prospects." Global Pharmaceutical Sciences Review IX, no. II (2024): 9-17. https://doi.org/10.31703/gpsr.2024(IX-II).02